Atezolizumab, hyaluronidase-tqjs 1875mg/30000 Units; per vial; soln for SC inj; preservative-free. Atezolizumab binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This ...
Amgen meanwhile is also running trials of a lower dose (240mg once-daily instead of the current 960mg once-daily formulation) at the FDA's request, which may improve the tolerability of treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback